New Clinical Trials Available at Texas Retina
Our physicians remain committed to participating in ongoing retina research, providing our patients with access to promising new treatments through clinical trials. In fact, our research program has grown to become one
read more
Dr. Abbey Publishes Research on Effectiveness of a Long-acting Injectable Steroid for Patients with Cystoid Macular Edema After Vitrectomy
Long-acting injectable steroids have emerged as a new way to treat chronic intraocular inflammation and cystoid macular edema (CME) that reduces the treatment frequency and burden for retina patients. Texas Retina’s Ashkan
read more Dr. Abbey Presented at the American Society of Retina Specialists 2023 Annual Meeting
Texas Retina Associates’ Ashkan M. Abbey, MD, recently presented at the 41st Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) held in Seattle. ASRS is the largest organization of
read more Dr. Abbey Contributes to Real-world Study of Faricimab for Neovascular Age-related Macular Degeneration
The TRUCKEE study is a real-world, collaborative effort to investigate the efficacy, durability, and safety of a monoclonal antibody treatment called faricimab in patients suffering from neovascular age-related macular degeneration (nAMD) in
read more New Clinical Trials Available
At Texas Retina Associates, our physicians remain actively involved in conducting research that will improve care for our patients, offering access to promising new retinal treatments through clinical trials. We recently opened
read more Dr. Abbey Featured in Retina Times
Texas Retina Associates’ Ashkan Abbey, MD, was featured in the “5 Questions” segment of the latest issue of Retina Today. In the article, he discusses his passion for retina research, what led
read more Four New Clinical Trials Available at Texas Retina Associates
Our physicians remain committed to participating in ongoing retina research and providing our patients access to promising new treatment options through clinical trials. We recently opened four new clinical trials: Diabetic Macular
read more
Texas Retina Associates First in the Country to Dose a Patient in the DAVIO 2 Clinical Trial
Texas Retina Associates is honored to have randomized the first patient in EyePoint Pharmaceuticals’ Phase 2 “Durasert and Vorolanib in Ophthalmology 2” (DAVIO 2) clinical trial of EYP-1901 for patients with wet macular
read more
Texas Retina Associates Announces the Retirement of David Callanan, MD
It is with mixed emotions that we announce the retirement of David Callanan, MD, from Texas Retina Associates effective June 30, 2022. He has been caring for patients at our practice since
read more
Dr. Abbey Spoke About Complications of a Compounded Medication Used in “Dropless” Cataract Surgery at the Vit-Buckle Society (VBS) Annual Meeting
Texas Retina Associates’ Ashkan M. Abbey, MD, presented “Complications of Compounded Moxifloxacin-Triamcinolone” at the 10th Annual Meeting of the Vit-Buckle Society (VBS) held March 24 – 26, 2022, in Las Vegas. He
read more